DeepMed Research

Dimethyltryptamine

Generic Name: Dimethyltryptamine

Drug Type: Small Molecule

Chemical Formula: C_₁₂H_₁₆N_₂

CAS Number: 61-50-7

Unique Ingredient Identifier: WUB601BHAA

Background: An N-methylated indoleamine derivative, a serotonergic hallucinogen found in several plants, especially Prestonia amazonica (Apocynaceae) and in mammalian brain, blood, and urine. It apparently acts as an agonist at some types of serotonin receptors and an antagonist at others.

Indication: Some people use this compound as a psychedelic inducing agent.

Clinical Trials

Phase 2 Clinical Trial of GH001 in Bipolar II Disorder

Phase 2

Terminated

Conditions: Bipolar II Disorder

Interventions: Drug: GH001

First Posted Date: 2023-05-03

Last Posted Date: 2025-02-18

Lead Sponsor: GH Research Ireland Limited

Target Recruit Count: 6

Registration Number: NCT05839509

Locations: 🇬🇧
Investigational Site, London, United Kingdom
🇬🇧
Investigation Site, Oxford, United Kingdom

Phase 2 Clinical Trial of GH001 in Postpartum Depression

Phase 2

Terminated

Conditions: Postnatal Depression
Postpartum Depression

Interventions: Drug: GH001

First Posted Date: 2023-04-07

Last Posted Date: 2025-02-18

Lead Sponsor: GH Research Ireland Limited

Target Recruit Count: 10

Registration Number: NCT05804708

Locations: 🇳🇱
Amsterdam UMC, Amsterdam, Netherlands
🇬🇧
Clerkenwell Health, London, United Kingdom
🇬🇧
St. Pancras Clinical Research, London, United Kingdom

and more 1 locations

A Trial of GH001 in Patients with Treatment-resistant Depression

Phase 2

Active, not recruiting

Conditions: Treatment-resistant Depression

Interventions: Drug: GH001
Drug: Placebo

First Posted Date: 2023-04-06

Last Posted Date: 2024-11-29

Lead Sponsor: GH Research Ireland Limited

Target Recruit Count: 80

Registration Number: NCT05800860

Locations: 🇮🇪
Investigational site, Dublin, Ireland
🇪🇸
Investigational Site, Salamanca, Spain

Mindfulness and Psychedelics

Early Phase 1

Completed

Conditions: Healthy Participants

Interventions: Drug: Placebo
Drug: DMT + harmine

First Posted Date: 2023-03-22

Last Posted Date: 2023-09-21

Lead Sponsor: Milan Scheidegger

Target Recruit Count: 40

Registration Number: NCT05780216

Locations: 🇨🇭
Psychiatric University Hospital Zurich, Zurich, Switzerland

Safety and Pharmacokinetics of GH002 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: 5 Methoxy N,N Dimethyltryptamine
Drug: Placebo

First Posted Date: 2023-03-03

Last Posted Date: 2024-01-25

Lead Sponsor: GH Research Ireland Limited

Target Recruit Count: 64

Registration Number: NCT05753956

Locations: 🇳🇱
GH Research Clinical Trial Site, Groningen, Netherlands

Acute Dose-dependent Effects of DMT-bolus Applications in Healthy Subjects (DMT BDR-Study)

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: N,N-Dimethyltryptamine (5mg)
Drug: N,N-Dimethyltryptamine (10mg)
Drug: N,N-Dimethyltryptamine (15mg)
Drug: N,N-Dimethyltryptamine (20mg)
Drug: Placebo (saline)
Drug: N,N-Dimethyltryptamine (25mg)

First Posted Date: 2023-01-25

Last Posted Date: 2025-04-11

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 36

Registration Number: NCT05695495

Locations: 🇨🇭
Clinical Pharmacology & Toxicology, University Hospital Basel, Basel, Switzerland

Clinical Study of DMT in Healthy Adults

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: N,N-Dimethyltryptamine

First Posted Date: 2022-10-10

Last Posted Date: 2023-02-15

Lead Sponsor: Biomind Labs Inc.

Target Recruit Count: 27

Registration Number: NCT05573568

Locations: 🇧🇷
Hospital Universitário Onofre Lopes, Natal, Rio Grande Do Norte, Brazil

Single and Repeat Doses of DMT in Healthy Subjects

Phase 1

Active, not recruiting

Conditions: Stroke

Interventions: Drug: N,N-Dimethyltryptamine
Drug: Placebo

First Posted Date: 2022-09-29

Last Posted Date: 2025-01-28

Lead Sponsor: Algernon Pharmaceuticals

Target Recruit Count: 60

Registration Number: NCT05559931

Locations: 🇳🇱
Centre for Human Drug Research, Leiden, Netherlands

Acute Dose-dependent Effects of DMT in Healthy Subjects

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: N,N-Dimethyltryptamine (162 mg)
Drug: N,N-Dimethyltryptamine (108 mg) + dose titration
Drug: N,N-Dimethyltryptamine (54 mg)
Drug: N,N-Dimethyltryptamine (108 mg)
Drug: N,N-Dimethyltryptamine (216 mg)
Drug: Placebo

First Posted Date: 2022-05-20

Last Posted Date: 2024-04-25

Lead Sponsor: University Hospital, Basel, Switzerland

Target Recruit Count: 24

Registration Number: NCT05384678

Locations: 🇨🇭
Universtity Hospital Basel, Basel, Switzerland

Pharmacokinetics of GH001 in Healthy Volunteers

Phase 1

Completed

Conditions: Healthy Volunteers

Interventions: Drug: 5 Methoxy N,N Dimethyltryptamine
Drug: Placebo

First Posted Date: 2021-12-20

Last Posted Date: 2021-12-20

Lead Sponsor: GH Research Ireland Limited

Target Recruit Count: 46

Registration Number: NCT05163691

Locations: 🇳🇱
GH Research Clinical Trial Site, Groningen, Netherlands

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy